In conclusion, PXR enhances the resistance of tumor cells to the chemotherapeutic agent L-OHP via direct transcriptional activating MRP3 expression, increasing the L-OHP efflux capacity of CRC cells (Fig. 8). Here, NR1I2 is linked to neoplasm.